{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:40:03Z","timestamp":1792194003007,"version":"4.4.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":376,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent one of the four pillars of heart failure (HF) pharmacological therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The study aims to clarify SGLT2i antiarrhythmic effect on patients with HF with reduced ejection fraction (HFrEF) in terms of atrial and ventricular arrhythmias (AAs and VAs) reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HFrEF carriers of implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) followed by remote monitoring of Policlinico Umberto I of Rome for 1 year before and after SGLT2i therapy initiation were enrolled in the study. We compared the incidence of AAs and VAs as recorded at remote monitoring during 1 year preceding SGLT2i therapy initiation and after 1 year of SGLT2i therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 198 enrolled patients, 135 patients had arrhythmic events before SGLT2i therapy prescription. There were 1353 arrhythmic events recorded in the year before SGLT2i therapy prescription, and 354 events were detected in the year after SGLT2i initiation, with a 73.8% reduction in events number after therapy initiation. After SGLT2i therapy initiation, the median number of total arrhythmic episodes significantly decreased from a median of 7 [3;12] to 1 [0;4] (P value &amp;lt; 0.001), AAs significantly decreased from a median of 4 [3;7] to 1 [0;3] episodes (P value &amp;lt; 0.001) and VAs were reduced from a median of 5.5 [3;10] to 0 [0;2] (P value &amp;lt; 0.001). When considering arrhythmia subtypes, larger reductions were recorded for atrial fibrillation (AF) episodes, reduced from 4 [3;8] to 0 [0;3], non-sustained ventricular tachycardia (NSVT) that decreased from 4 [2;8.75] to 0 [0;2] (P value &amp;lt; 0.001) and for sustained ventricular tachycardia (SVT) that were reduced from 3 [2;4] to 0 [0;1] (P value &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In HFrEF carriers of ICD\/CRT-D, the use of SGLT2i resulted in significant reduction of AA and VA events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15223","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T01:57:32Z","timestamp":1739239052000},"page":"2125-2133","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["SGLT2i Reduce Arrhythmic Events in Heart Failure Patients with Cardiac Implantable Electronic Devices"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-1209","authenticated-orcid":false,"given":"Marco Valerio","family":"Mariani","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Lavalle","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Palombi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pierucci","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Trivigno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"D'Amato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Filomena","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cipollone","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Laviola","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Piro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Prosperi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Magliolo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Myftari","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Mirco","family":"La Fazia","sequence":"additional","affiliation":[{"name":"St. David's Medical Center, Texas Cardiac Arrhythmia Institute , Austin, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Severino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Badagliacca","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine Dario","family":"Vizza","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences \u2018Sapienza\u2019, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2026021804280764400_ehf215223-bib-0001","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.115.018614","article-title":"Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction","volume":"133","author":"Santhanakrishnan","year":"2016","journal-title":"Circulation"},{"key":"2026021804280764400_ehf215223-bib-0002","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"2026021804280764400_ehf215223-bib-0003","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.jacc.2006.01.060","article-title":"Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"47","author":"Olsson","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"key":"2026021804280764400_ehf215223-bib-0004","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"European Heart Journal"},{"key":"2026021804280764400_ehf215223-bib-0005","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"European Heart Journal"},{"key":"2026021804280764400_ehf215223-bib-0006","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/s41598-023-30349-w","article-title":"Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation","volume":"13","author":"Dong","year":"2023","journal-title":"Scientific Reports"},{"key":"2026021804280764400_ehf215223-bib-0007","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ejhf.2419","article-title":"Effect of sacubitril\/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF","volume":"24","author":"Curtain","year":"2022","journal-title":"European Journal of Heart Failure"},{"key":"2026021804280764400_ehf215223-bib-0008","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"European Heart Journal"},{"key":"2026021804280764400_ehf215223-bib-0009","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"2026021804280764400_ehf215223-bib-0010","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of\u2009 &gt;\u200980,000 patients (the SGLT2i\u2014arrhythmias and sudden cardiac death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovascular Diabetology"},{"key":"2026021804280764400_ehf215223-bib-0011","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.hrthm.2015.11.018","article-title":"2015 HRS\/EHRA\/APHRS\/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing","volume":"13","author":"Wilkoff","year":"2016","journal-title":"Heart Rhythm"},{"key":"2026021804280764400_ehf215223-bib-0012","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/j.hrthm.2019.02.034","article-title":"2019 HRS\/EHRA\/APHRS\/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing","volume":"17","author":"Stiles","year":"2020","journal-title":"Heart Rhythm"},{"key":"2026021804280764400_ehf215223-bib-0013","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40001-020-0401-x","article-title":"Clinical significance of precedent asymptomatic non-sustained ventricular tachycardias on subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients","volume":"25","author":"Makimoto","year":"2020","journal-title":"European Journal of Medical Research"},{"key":"2026021804280764400_ehf215223-bib-0014","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa071098","article-title":"Prognostic importance of defibrillator shocks in patients with heart failure","volume":"359","author":"Poole","year":"2008","journal-title":"The New England Journal of Medicine"},{"key":"2026021804280764400_ehf215223-bib-0015","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051316","article-title":"Anti-arrhythmic effects of heart failure guideline-directed medical therapy and their role in the prevention of sudden cardiac death: from beta-blockers to sodium-glucose cotransporter 2 inhibitors and beyond","volume":"13","author":"Zaher","year":"2024","journal-title":"Journal of Clinical Medicine"},{"key":"2026021804280764400_ehf215223-bib-0016","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"2026021804280764400_ehf215223-bib-0017","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jce.16344","article-title":"SGLT2i effect on atrial fibrillation: a network meta-analysis of randomized controlled trials","volume":"35","author":"Mariani","year":"2024","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"2026021804280764400_ehf215223-bib-0018","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/pace.14704","article-title":"Effect of SGLT-2 inhibitors as an add-on therapy to metformin on P wave indices and atrial electromechanics in type 2 diabetes mellitus patients","volume":"46","author":"Ziyrek","year":"2023","journal-title":"Pacing and Clinical Electrophysiology"},{"key":"2026021804280764400_ehf215223-bib-0019","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/jce.15996","article-title":"Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices","volume":"34","author":"Younis","year":"2023","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"2026021804280764400_ehf215223-bib-0020","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","article-title":"Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation","volume":"108","author":"Huxley","year":"2011","journal-title":"The American Journal of Cardiology"},{"key":"2026021804280764400_ehf215223-bib-0021","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42444-024-00109-6","article-title":"SGLT2 inhibitors and the cardiac rhythm: unraveling the connections","volume":"25","author":"Paul","year":"2024","journal-title":"International Journal of Arrhythmia"},{"key":"2026021804280764400_ehf215223-bib-0022","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.009979","article-title":"Nonsustained ventricular tachycardia is independently associated with sustained ventricular arrhythmias in nonischemic dilated cardiomyopathy","volume":"15","author":"Piers","year":"2022","journal-title":"Circulation: Arrhythmia and Electrophysiology"},{"key":"2026021804280764400_ehf215223-bib-0023","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004875","article-title":"Cardiac resynchronization therapy reduces ventricular arrhythmias in primary but not secondary prophylactic implantable cardioverter defibrillator patients: insight from the resynchronization in ambulatory heart failure trial","volume":"10","author":"Sapp","year":"2017","journal-title":"Circulation: Arrhythmia and Electrophysiology"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2125\/66956338\/eschf_12_3_2125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/2125\/66956338\/eschf_12_3_2125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:28:12Z","timestamp":1771406892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/2125\/8488373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15223","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"2024-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}